AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8161320 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine Bromide (PB) 90 mg per day
Number of subjects: 0
Study 8161320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3283384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (prophylactic course, dosage not specified)
Number of subjects: 0
Study 3283384 — intervention group
Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 0
Study 31983605 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin for one week before biopsy continuing for one week after biopsy
Number of subjects: 112
Study 31983605 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alpha-blocker treatment)
Number of subjects: 112
Study 29925127 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 30
Study 27097977 — intervention group
Group type: EXPERIMENTAL
Intervention: ivacaftor
Number of subjects: 161
Study 27097977 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary exacerbations (PEs) requiring hospitalization
Number of subjects: 161
Study 27097977 — intervention group
Group type: EXPERIMENTAL
Intervention: ppFEV1
Number of subjects: 161
Study 27097977 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 161
Study 25720546 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole nitrate vaginal suppository 1,200 mg
Number of subjects: 577
Study 25720546 — intervention group
Group type: COMPARATOR
Intervention: Oral fluconazole 150 mg
Number of subjects: 577
Study 23259453 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir 10 mg daily for 48 weeks
Number of subjects: 0
Study 23259453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21157043 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 M alum mouthrinse
Number of subjects: 3
Study 21157043 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated saline rinse
Number of subjects: 3
Study 21157043 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (placebo) rinse
Number of subjects: 3
Study 19001325 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin)
Number of subjects: 1691
Study 19001325 — intervention group
Group type: COMPARATOR
Intervention: IFL (irinotecan plus bolus fluorouracil and leucovorin)
Number of subjects: 1691
Study 19001325 — intervention group
Group type: COMPARATOR
Intervention: IROX (bolus irinotecan/oxaliplatin)
Number of subjects: 1691
Study 16611389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation (1 g ascorbic acid 2 hours pre- and for 14 days post-exercise)
Number of subjects: 0
Study 16611389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation
Number of subjects: 0
Study 16611389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14662633 — intervention group
Group type: EXPERIMENTAL
Intervention: The COACH Program (coaching via telephone and mailings)
Number of subjects: 792
Study 14662633 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 792
Study 14662633 — intervention group
Group type: EXPERIMENTAL
Intervention: The COACH Program
Number of subjects: 792
Study 10913806 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with a beneficial effect on the nonfatal outcome
Number of subjects: 0
Study 10913806 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment effect on mortality)
Number of subjects: 0
Study 8853764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (5-HT3 antagonist)
Number of subjects: 50
Study 8853764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1479514 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibro-acoustic stimulation
Number of subjects: 21
Study 1479514 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 21
Study 6725789 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively ionized air
Number of subjects: 36
Study 6725789 — intervention group
Group type: COMPARATOR
Intervention: Air-placebo condition
Number of subjects: 36
Study 30204518 — intervention group
Group type: EXPERIMENTAL
Intervention: Hook Grip (HG)
Number of subjects: 11
Study 30204518 — intervention group
Group type: COMPARATOR
Intervention: Closed Grip
Number of subjects: 11
Study 27551990 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cycling
Number of subjects: 60
Study 27551990 — intervention group
Group type: COMPARATOR
Intervention: Passive cycling (placebo)
Number of subjects: 60
Study 25678394 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoembolization with GM-CSF
Number of subjects: 52
Study 25678394 — intervention group
Group type: COMPARATOR
Intervention: Bland embolization (BE)
Number of subjects: 52
Study 24329816 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillation applicator
Number of subjects: 20
Study 24329816 — intervention group
Group type: COMPARATOR
Intervention: Hand application
Number of subjects: 20
Study 22527628 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior fossa decompression (PFD) only in group Ia (12 cases)
Number of subjects: 46
Study 22527628 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior fossa decompression (PFD) with fourth ventricular shunt in group Ib (14 cases)
Number of subjects: 46
Study 22527628 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior fossa decompression (PFD) and syringosubarachnoid shunt in group Ic (6 cases)
Number of subjects: 46
Study 22527628 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior fossa decompression (PFD) only in group II (14 cases)
Number of subjects: 46
Study 22527628 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative MRI results
Number of subjects: 46
Study 22527628 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence of symptoms
Number of subjects: 46
Study 22527628 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringosubarachnoid shunting
Number of subjects: 46
Study 22527628 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth ventricular shunt in cases of syringomyelia
Number of subjects: 46
Study 19262985 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic subfascial polypropylene mesh reinforcement of midline closure (Group A)
Number of subjects: 40
Study 19262985 — intervention group
Group type: COMPARATOR
Intervention: Conventional method only (Group B)
Number of subjects: 40
Study 19262985 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 17461928 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg day(‐1))
Number of subjects: 20
Study 15175199 — intervention group
Group type: COMPARATOR
Intervention: Frontal chest radiograph alone (Group 1)
Number of subjects: 570
Study 15175199 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal and lateral chest radiographs (Group 2)
Number of subjects: 570
Study 11201769 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive corporate wellness effort
Number of subjects: 0
Study 11201769 — intervention group
Group type: EXPERIMENTAL
Intervention: Workers' compensation and disability program interventions
Number of subjects: 0
Study 11201769 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated program
Number of subjects: 0
Study 9273008 — intervention group
Group type: EXPERIMENTAL
Intervention: Amidotrizoate (ionic contrast medium)
Number of subjects: 20
Study 9273008 — intervention group
Group type: COMPARATOR
Intervention: Iopromid (non-ionic contrast medium)
Number of subjects: 20
Study 8108609 — intervention group
Group type: EXPERIMENTAL
Intervention: Small amplitude (SO) hypoxic stimulation (PET(O2) from 63.2 to 54.9 Torr) at 2 Torr above resting PET(CO2) (EC)
Number of subjects: 5
Study 8108609 — intervention group
Group type: EXPERIMENTAL
Intervention: Large amplitude (LO) hypoxic stimulation (PET(O2) from 73.0 to 48.0 Torr) at 2 Torr above resting PET(CO2) (EC)
Number of subjects: 5
Study 8108609 — intervention group
Group type: EXPERIMENTAL
Intervention: Small amplitude (SO) hypoxic stimulation (PET(O2) from 63.2 to 54.9 Torr) at 7 Torr above resting PET(CO2) (HC)
Number of subjects: 5
Study 8108609 — intervention group
Group type: EXPERIMENTAL
Intervention: Large amplitude (LO) hypoxic stimulation (PET(O2) from 73.0 to 48.0 Torr) at 7 Torr above resting PET(CO2) (HC)
Number of subjects: 5
Study 3802708 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 80 mg
Number of subjects: 0
Study 3802708 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg
Number of subjects: 0
Study 29087622 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 21
Study 29087622 — intervention group
Group type: COMPARATOR
Intervention: Omnivorous diet
Number of subjects: 21
Study 27169919 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg/day)
Number of subjects: 51
Study 27169919 — intervention group
Group type: COMPARATOR
Intervention: Cilostazol (‐)
Number of subjects: 51
Study 25039997 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-based radiofrequency renal denervation (RDN)
Number of subjects: 39
Study 25039997 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment (Control)
Number of subjects: 39
Study 22230154 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide with matched hydration (FMH group, n = 87)
Number of subjects: 170
Study 22230154 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous isotonic saline hydration (control group, n = 83)
Number of subjects: 170
Study 20819439 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin-absorbed collagen sponges placed on the sacral fascia, no oral post-operative antibiotics.
Number of subjects: 80
Study 20819439 — intervention group
Group type: COMPARATOR
Intervention: Oral antibiotics for 7 days post-operatively (Control group).
Number of subjects: 80
Study 18487550 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone after docetaxel
Number of subjects: 232
Study 18487550 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel after mitoxantrone
Number of subjects: 232
Study 18487550 — intervention group
Group type: COMPARATOR
Intervention: Crossover therapy
Number of subjects: 232
Study 15953249 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) laser irradiation at 8 J.cm(‐2)
Number of subjects: 33
Study 15953249 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) laser irradiation at 16 J.cm(‐2)
Number of subjects: 33
Study 15953249 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser irradiation)
Number of subjects: 33
Study 14506488 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g CLA per day
Number of subjects: 54
Study 14506488 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 g CLA per day
Number of subjects: 54
Study 14506488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 11204323 — intervention group
Group type: COMPARATOR
Intervention: ApoE genotype determination
Number of subjects: 45
Study 11204323 — intervention group
Group type: COMPARATOR
Intervention: Tau protein level measurement in cerebro-spinal fluid (CSF)
Number of subjects: 45
Study 8836932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (L-DOPA/benserazide + bromocriptine, nearly 40% replacement)
Number of subjects: 674
Study 8836932 — intervention group
Group type: COMPARATOR
Intervention: Levodopa monotherapy
Number of subjects: 674
Study 8836932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (L-DOPA/benserazide + bromocriptine)
Number of subjects: 674
Study 8836932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (L-DOPA/benserazide + bromocriptine) with > 50% substitution
Number of subjects: 674
Study 1998929 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric day hospital treatment
Number of subjects: 113
Study 1998929 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 113
Study 6367345 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded compression of the calf
Number of subjects: 62
Study 31147367 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperuricaemia (HUA) defined as serum uric acid level >420 μmol/L in men and >360 μmol/L in women
Number of subjects: 11488
Study 31147367 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperuricaemia (HUA)
Number of subjects: 11488
Study 31147367 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid level
Number of subjects: 11488
Study 31147367 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, living in urban areas, alcohol consumption, central obesity, elevated fasting plasma glucose level, elevated blood pressure, lower high-density lipoprotein cholesterol level, elevated triglycerides level
Number of subjects: 11488
Study 31147367 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-valvular atrial fibrillation (NVAF) diagnosed as per guidelines
Number of subjects: 11488
Study 29274162 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) by Diode Laser GaAlAs (780nm), twice a week for six weeks
Number of subjects: 66
Study 29274162 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic infiltration of lidocaine 2% without vasoconstrictor, once a week for four weeks
Number of subjects: 66
Study 29274162 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (LLLT and lidocaine infiltration)
Number of subjects: 66
Study 27403531 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture catgut embedding therapy (ACET) with moxibustion
Number of subjects: 0
Study 27403531 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 0
Study 25023152 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week early exercise and education programme
Number of subjects: 60
Study 25023152 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 22554184 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized 12-week aerobic cycling training (TG)
Number of subjects: 18
Study 22554184 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 18
Study 20600185 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa intake
Number of subjects: 0
Study 20600185 — intervention group
Group type: COMPARATOR
Intervention: No performance feedback
Number of subjects: 0
Study 18047460 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk stabilisation exercises
Number of subjects: 9
Study 18047460 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercises)
Number of subjects: 9
Study 16131672 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood salvage and reinfusion system
Number of subjects: 60
Study 16131672 — intervention group
Group type: COMPARATOR
Intervention: Standard allogeneic blood transfusion
Number of subjects: 60
Study 11874215 — intervention group
Group type: COMPARATOR
Intervention: Clinician-guided behavior therapy
Number of subjects: 218
Study 11874215 — intervention group
Group type: COMPARATOR
Intervention: Computer-guided behavior therapy
Number of subjects: 218
Study 11874215 — intervention group
Group type: COMPARATOR
Intervention: Systematic relaxation
Number of subjects: 218
Study 10208072 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute training procedure based on the Carleton Skill Training Program
Number of subjects: 98
Study 10208072 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttreatment suggestibility scores
Number of subjects: 98
Study 8639349 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of bias at entry (randomization)
Number of subjects: 91
Study 2140743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg b.i.d.)
Number of subjects: 40
Study 2140743 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25 mg b.i.d.)
Number of subjects: 40
Study 2140743 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ketanserin and captopril (20 mg b.i.d. and 25 mg b.i.d. respectively) for 45 days
Number of subjects: 40
Study 6213682 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clindamycin (1% solution)
Number of subjects: 305
Study 6213682 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tetracycline (250 mg)
Number of subjects: 305
Study 6213682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 31877703 — intervention group
Group type: EXPERIMENTAL
Intervention: Street Food (SF)
Number of subjects: 189
Study 31877703 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Foods (FF)
Number of subjects: 189
Study 31877703 — intervention group
Group type: EXPERIMENTAL
Intervention: Artisanal Foods (AF)
Number of subjects: 189
Study 29315665 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 44
Study 29315665 — intervention group
Group type: COMPARATOR
Intervention: Control (sham RIPC)
Number of subjects: 44
Study 27998863 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged retrograde flexible ureteroscopic lithotripsy (FURS)
Number of subjects: 70
Study 27998863 — intervention group
Group type: COMPARATOR
Intervention: Miniaturized percutaneous nephrolithotomy (m-PCNL)
Number of subjects: 70
Study 25311693 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver knowledge of diarrhea prevention practices
Number of subjects: 952
Study 25311693 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver knowledge of food safety practices
Number of subjects: 952
Study 25311693 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion interventions
Number of subjects: 952
Study 21925813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrahepatic vein transfusion (IHV group)
Number of subjects: 19
Study 21925813 — intervention group
Group type: COMPARATOR
Intervention: Umbilical vein transfusion (PCI group)
Number of subjects: 19
Study 19139160 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative task
Number of subjects: 0
Study 19139160 — intervention group
Group type: EXPERIMENTAL
Intervention: Being informed that creativity is culturally valued
Number of subjects: 0
Study 19139160 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 0
Study 19139160 — intervention group
Group type: COMPARATOR
Intervention: Control topic
Number of subjects: 0
Study 17924899 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable laryngeal tube (LT‐D)
Number of subjects: 100
Study 17924899 — intervention group
Group type: COMPARATOR
Intervention: Reusable laryngeal tube (LT‐R)
Number of subjects: 100
Study 17924899 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LT‐D and LT‐R
Number of subjects: 100
Study 17924899 — intervention group
Group type: EXPERIMENTAL
Intervention: LT‐D
Number of subjects: 100
Study 17924899 — intervention group
Group type: EXPERIMENTAL
Intervention: LT‐R
Number of subjects: 100
Study 16495752 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg to 100 mg daily for 6 months
Number of subjects: 30
Study 16495752 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg to 100 mg daily for 6 months
Number of subjects: 30
Study 12558613 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% inclination
Number of subjects: 11
Study 12558613 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% inclination
Number of subjects: 11
Study 12558613 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% inclination
Number of subjects: 11
Study 12558613 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 12% inclination to 4% and 8%
Number of subjects: 11
Study 10755337 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemorrhoidectomy plus lateral internal sphincterotomy (LIS)
Number of subjects: 42
Study 10755337 — intervention group
Group type: COMPARATOR
Intervention: Haemorrhoidectomy alone
Number of subjects: 42
Study 10755337 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral internal sphincterotomy (LIS)
Number of subjects: 42
Study 8638801 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg/kg
Number of subjects: 20
Study 8638801 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg
Number of subjects: 20
Study 1355595 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologically guided drug therapy
Number of subjects: 170
Study 1355595 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol therapy
Number of subjects: 170
Study 1355595 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol therapy (for noninducible arrhythmia)
Number of subjects: 170
Study 1355595 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologically guided drug therapy (for inducible arrhythmia that became noninducible)
Number of subjects: 170
Study 1355595 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol therapy (for inducible arrhythmia that remained inducible)
Number of subjects: 170
Study 6517245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose droperidol (0.25 mg)
Number of subjects: 0
Study 6517245 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose droperidol (1.25 mg)
Number of subjects: 0
Study 6517245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31968622 — intervention group
Group type: EXPERIMENTAL
Intervention: Infracyanine Green (IFCG)
Number of subjects: 39
Study 31968622 — intervention group
Group type: EXPERIMENTAL
Intervention: Brilliant Blue G (BBG)
Number of subjects: 39
Study 29329763 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (titrated to two 0.5 mg doses twice daily)
Number of subjects: 248
Study 29329763 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 248
Study 29329763 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (mITT analysis)
Number of subjects: 248
Study 29329763 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mITT analysis)
Number of subjects: 248
Study 29329763 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 248
Study 29329763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 27781970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound simulator devices during critical care simulation
Number of subjects: 0
Study 27781970 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25670823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam (1.5 g) plus metronidazole (500 mg) every 8 hours for 4-14 days
Number of subjects: 806